{"id":"W2202588822","doi":"10.1159/000381589","title":"A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium","year":2015,"lang":"en","type":"article","venue":"Urologia Internationalis","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"ca_institutions":"Steinbach Bible College","funders":"AstraZeneca","keywords":"Medicine; Gefitinib; Gemcitabine; Chemotherapy; Internal medicine; Oncology; Concomitant; Tolerability; Phases of clinical research; Nausea; Epidermal growth factor receptor; Clinical endpoint; Adverse effect; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004521981,0.001941495,0.00260765,0.0005570459,0.0006136321,0.001057621,0.0009262308,0.001800515,0.003420623],"category_scores_gemma":[0.001571844,0.0007220516,0.001976892,0.0005461072,0.001499267,0.0007800544,0.000381479,0.003354839,0.0007366629],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009093336,"about_ca_system_score_gemma":0.002616631,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007126507,"about_ca_topic_score_gemma":0.001478759,"domain_scores_codex":[0.99896,0.0006590174,0.00004823799,0.0001495457,0.00007822135,0.0001049328],"domain_scores_gemma":[0.9983681,0.000282624,0.0003267415,0.0001724494,0.0001534388,0.0006967774],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9210204,0.03435178,0.003375028,0.0004379782,0.00164167,0.00009243931,0.0001147603,0.0007261432,0.01255269,0.0001745775,0.001916203,0.02359646],"study_design_scores_gemma":[0.8930839,0.1009268,0.003159739,0.00001192361,0.0004683926,0.00005792555,0.00001181738,0.0002671774,0.001088085,0.00006399702,0.0008468289,0.00001341697],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9877937,0.002875894,0.0008773908,0.0008350206,0.0002828135,0.004299802,0.00116391,0.00007344426,0.001797995],"genre_scores_gemma":[0.9814549,0.002377419,0.003172619,0.001407849,0.0004982974,0.005178141,0.00291355,0.00003536911,0.002961815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004521981,"threshold_uncertainty_score":0.02391481,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1165180056392242,"score_gpt":0.3822319459424833,"score_spread":0.2657139403032591,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}